These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36299300)

  • 1. Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components.
    Hsu SK; Jadhao M; Liao WT; Chang WT; Hung CT; Chiu CC
    Front Mol Biosci; 2022; 9():1020888. PubMed ID: 36299300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Exosomes in Pancreatic Ductal Adenocarcinoma Progression and Their Potential as Biomarkers.
    Hsu SK; Jadhao M; Liao WT; Chang WT; Lin IL; Chiu CC
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Olaoba OT; Yang M; Adelusi TI; Maidens T; Kimchi ET; Staveley-O'Carroll KF; Li G
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new era: tumor microenvironment in chemoresistance of pancreatic cancer.
    Zhao X; Li Z; Gu Z
    J Cancer Sci Clin Ther; 2022; 6(1):61-86. PubMed ID: 35187493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches.
    Truong LH; Pauklin S
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities.
    Myo Min KK; Ffrench CB; Jessup CF; Shepherdson M; Barreto SG; Bonder CS
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers and opportunities in pancreatic cancer immunotherapy.
    Ju Y; Xu D; Liao MM; Sun Y; Bao WD; Yao F; Ma L
    NPJ Precis Oncol; 2024 Sep; 8(1):199. PubMed ID: 39266715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic Tumor Microenvironment.
    Wang K; He H
    Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment and metabolic remodeling in gemcitabine-based chemoresistance of pancreatic cancer.
    Gu Z; Du Y; Zhao X; Wang C
    Cancer Lett; 2021 Aug; 521():98-108. PubMed ID: 34461181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches.
    Carvalho TMA; Di Molfetta D; Greco MR; Koltai T; Alfarouk KO; Reshkin SJ; Cardone RA
    Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment.
    Yamamoto K; Iwadate D; Kato H; Nakai Y; Tateishi K; Fujishiro M
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic Stromal Depletion in Pancreatic Ductal Adenocarcinoma.
    Lintern N; Smith AM; Jayne DG; Khaled YS
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer.
    Wandmacher AM; Letsch A; Sebens S
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours.
    Huang HC; Sung YC; Li CP; Wan D; Chao PH; Tseng YT; Liao BW; Cheng HT; Hsu FF; Huang CC; Chen YT; Liao YH; Hsieh HT; Shih YC; Liu IJ; Wu HC; Lu TT; Wang J; Chen Y
    Gut; 2022 Sep; 71(9):1843-1855. PubMed ID: 34921062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities.
    Young K; Hughes DJ; Cunningham D; Starling N
    Ther Adv Med Oncol; 2018; 10():1758835918816281. PubMed ID: 30574212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives.
    Wu Y; Zhang C; Jiang K; Werner J; Bazhin AV; D'Haese JG
    Front Oncol; 2020; 10():621937. PubMed ID: 33520728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
    Lafaro KJ; Melstrom LG
    Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.